Advair
Product Images NDC 21695-361

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Advair (NDC 21695-361). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Cumulative Incidence Of Asthma-related Deaths In The 28-week Salmeterol Multi-center Asthma Research Trial (smart), By Duration Of Treatment (0bfe9d76 1b0e 47a4 831d 097168d66577 01)

This image contains three line graphs depicting cumulative incidence of asthma-related death over treatment duration in days for all subjects, Caucasian, and African American populations, comparing Salmeterol and Placebo groups. Each graph includes a table showing the number of subjects at risk at various time intervals for both treatment groups.*

FDA Label Image

Fluticasone Propionate Chemical Structure (0bfe9d76 1b0e 47a4 831d 097168d66577 02)

Chemical structure diagram showing the molecular layout of the active ingredient in ADVAIR DISKUS by Rebel Distributors Corp, NDC 21695-361. The structure includes multiple rings, hydroxyl (OH), fluorine (F), and other functional groups characteristic of the compound.*

FDA Label Image

Salmeterol Xinafoate Chemical Structure (0bfe9d76 1b0e 47a4 831d 097168d66577 03)

Chemical structure diagram depicting two active ingredient molecules, consistent with those found in ADVAIR DISKUS by Rebel Distributors Corp. The structure shows characteristic rings and hydroxyl groups typical of the medication's components.*

FDA Label Image

Figure 2. Mean Percent Change From Baseline In Fev1 In Patients With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (study 1) (0bfe9d76 1b0e 47a4 831d 097168d66577 04)

A line graph showing the percentage change in FEV1 over 12 weeks for four groups: ADVAIR DISKUS 100/50 twice daily, Fluticasone propionate 100 mcg twice daily, Salmeterol 50 mcg twice daily, and placebo. The graph tracks changes from week 0 to endpoint, with ADVAIR DISKUS showing the highest improvement.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Patients With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (study 1) (0bfe9d76 1b0e 47a4 831d 097168d66577 05)

A line graph showing percent change in FEV1 over 12 hours on Day 1 baseline for four groups: ADVAIR DISKUS 100/50 twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and placebo. ADVAIR DISKUS shows the highest increase, peaking near hour 3, with others below it.*

FDA Label Image

Figure 4. Percent Change In Serial 12-hour Fev1 In Patients With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (study 1) (0bfe9d76 1b0e 47a4 831d 097168d66577 06)

Line graph depicting percentage change in FEV1 relative to Day 1 baseline over a 12-hour period for different treatments: ADVAIR DISKUS 100/50 twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and placebo. The graph shows time in hours on the x-axis and percentage change on the y-axis, illustrating comparative respiratory function changes among the groups.*

FDA Label Image

Figure 5. Predose Fev1: Mean Percent Change From Baseline In Patients With Chronic Obstructive Pulmonary Disease (0bfe9d76 1b0e 47a4 831d 097168d66577 07)

A line graph showing percentage change in FEV1 over 24 weeks for three groups: ADVAIR DISKUS 250/50 twice daily, Salmeterol 50 mcg twice daily, and placebo. The graph tracks changes from baseline FEV1 values, with ADVAIR DISKUS demonstrating the highest improvement across the study period.*

FDA Label Image

Figure 6. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Patients With Chronic Obstructive Pulmonary Disease (0bfe9d76 1b0e 47a4 831d 097168d66577 08)

Line chart depicting percent change in FEV1 over a 24-week period for ADVAIR DISKUS 250/50, fluticasone propionate 250 mcg, and placebo groups. The graph shows treatment effects on baseline FEV1 values measured at multiple time points, with sample sizes noted at baseline, 12 weeks, and study endpoint.*

FDA Label Image

Diskus Parts (0bfe9d76 1b0e 47a4 831d 097168d66577 09)

An illustration of an ADVAIR DISKUS inhaler device labeled with parts: Lever, Mouthpiece, Dose Indicator, Thumbgrip, and Outer Case. The center label shows the strength as 100/50 mcg fluticasone propionate and salmeterol inhalation powder.*

FDA Label Image

Figure 1 (0bfe9d76 1b0e 47a4 831d 097168d66577 10)

The image shows a close-up of an ADVAIR DISKUS inhaler device produced by Rebel Distributors Corp. Visible is the gray plastic inhaler mouthpiece with a label partially visible on the body, indicating the product's name and usage instructions. The design features a thumb grip and a dose counter window.*

FDA Label Image

Figure 2 (0bfe9d76 1b0e 47a4 831d 097168d66577 11)

An instructional illustration showing a hand holding an ADVAIR DISKUS inhaler. The image depicts the proper grip and a directional arrow indicating the motion required to open or operate the device.*

FDA Label Image

Figure 3 (0bfe9d76 1b0e 47a4 831d 097168d66577 12)

Illustration showing two hands holding an ADVAIR DISKUS inhaler, demonstrating how to hold and operate the device by rotating the lever to prepare a dose for inhalation.*

FDA Label Image

Figure 4 (0bfe9d76 1b0e 47a4 831d 097168d66577 13)

An illustration showing a person holding an inhaler device close to their mouth, demonstrating the proper use or technique for inhalation.*

FDA Label Image

Figure 5 (0bfe9d76 1b0e 47a4 831d 097168d66577 14)

An illustration showing a person using an inhaler device. The individual is holding the inhaler near their mouth, preparing to inhale the medication. The image likely demonstrates correct usage technique for an inhaled drug product.*

FDA Label Image

Figure 6 (0bfe9d76 1b0e 47a4 831d 097168d66577 15)

An instructional illustration showing two hands holding an ADVAIR DISKUS inhaler device. The image demonstrates the user rotating the inhaler, as indicated by an arrow, likely to prepare it for use.*

FDA Label Image

Advair Diskus 100/500mcg (0bfe9d76 1b0e 47a4 831d 097168d66577 16)

Label for ADVAIR DISKUS 100/50mcg powder inhaler by Rebel Distributors Corp. It includes dosage strength (100mcg fluticasone propionate and 50mcg salmeterol base), NDC 21695-361-60, Product ID RA036160, and manufacturer information (GSK, Kent, England). The label has storage instructions and is marked RX only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.